TXMD TherapeuticsMD, Inc.

Nasdaq therapeuticsmd.com


$ 1.03 $ 0.00 (0 %)    

Wednesday, 15-Oct-2025 18:38:15 EDT
QQQ $ 602.61 $ 4.22 (0.71 %)
DIA $ 463.04 $ 0.00 (0 %)
SPY $ 665.11 $ 2.94 (0.44 %)
TLT $ 90.76 $ -0.20 (-0.22 %)
GLD $ 387.41 $ 6.60 (1.73 %)
$ 1.04
$ 1.03
$ 1.03 x 607
$ 1.05 x 1,300
$ 1.03 - $ 1.04
$ 0.70 - $ 2.44
16,515
na
12.04M
$ 0.74
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2025 06-30-2025 10-Q
2 05-13-2025 03-31-2025 10-Q
3 03-27-2025 12-31-2024 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-12-2024 06-30-2024 10-Q
6 05-10-2024 03-31-2024 10-Q
7 03-29-2024 12-31-2023 10-K
8 11-14-2023 09-30-2023 10-Q
9 08-14-2023 06-30-2023 10-Q
10 05-15-2023 03-31-2023 10-Q
11 04-07-2023 12-31-2022 10-K
12 11-14-2022 09-30-2022 10-Q
13 08-15-2022 06-30-2022 10-Q
14 05-16-2022 03-31-2022 10-Q
15 03-23-2022 12-31-2021 10-K
16 11-12-2021 09-30-2021 10-Q
17 08-04-2021 06-30-2021 10-Q
18 05-06-2021 03-31-2021 10-Q
19 03-04-2021 12-31-2020 10-K
20 11-09-2020 09-30-2020 10-Q
21 08-07-2020 06-30-2020 10-Q
22 05-06-2020 03-31-2020 10-Q
23 02-24-2020 12-31-2019 10-K
24 11-08-2019 09-30-2019 10-Q
25 08-09-2019 06-30-2019 10-Q
26 05-08-2019 03-31-2019 10-Q
27 02-27-2019 12-31-2018 10-K
28 11-08-2018 09-30-2018 10-Q
29 07-30-2018 06-30-2018 10-Q
30 05-07-2018 03-31-2018 10-Q
31 02-23-2018 12-31-2017 10-K
32 11-07-2017 09-30-2017 10-Q
33 08-03-2017 06-30-2017 10-Q
34 05-03-2017 03-31-2017 10-Q
35 02-28-2017 12-31-2016 10-K
36 11-04-2016 09-30-2016 10-Q
37 08-05-2016 06-30-2016 10-Q
38 05-05-2016 03-31-2016 10-Q
39 02-26-2016 12-31-2015 10-K
40 11-05-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 therapeuticsmd-q2-eps-005-up-from-009-yoy-sales-1000m-up-from-234000k-yoy

TherapeuticsMD (NASDAQ:TXMD) reported quarterly earnings of $0.05 per share. This is a 155.56 percent increase over losses of $...

 therapeuticsmd-q1-eps-006-up-from-007-yoy-sales-39300k-up-from-31300k-yoy

TherapeuticsMD (NASDAQ:TXMD) reported quarterly losses of $(0.06) per share. This is a 14.29 percent increase over losses of $(...

 therapeuticsmd-q3-eps-005-up-from-013-yoy-sales-54700k-up-from-5300k-yoy

TherapeuticsMD (NASDAQ:TXMD) reported quarterly losses of $(0.05) per share. This is a 61.54 percent increase over losses of $(...

 therapeuticsmd-q2-eps-009-up-from-024-yoy-sales-23400k-down-from-43700k-yoy

TherapeuticsMD (NASDAQ:TXMD) reported quarterly losses of $(0.09) per share. This is a 62.5 percent increase over losses of $(0...

 therapeuticsmd-q1-eps-007-up-from-024-yoy

TherapeuticsMD (NASDAQ:TXMD) reported quarterly losses of $(0.07) per share. This is a 70.83 percent increase over losses of $(...

 therapeuticsmd-q3-eps-013-misses-005-estimate

TherapeuticsMD (NASDAQ:TXMD) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0....

 stocks-that-hit-52-week-lows-on-thursday

  During the session on Thursday, 461 stocks hit new 52-week lows.

 cantor-fitzgerald-reiterates-neutral-on-therapeuticsmd-maintains-5-price-target

Cantor Fitzgerald analyst Louise Chen reiterates TherapeuticsMD (NASDAQ:TXMD) with a Neutral and maintains $5 price target.

 therapeuticsmd-q2-eps-024-misses-007-estimate-sales-from-cont-ops-40000k-miss-50000k-estimate

TherapeuticsMD (NASDAQ:TXMD) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0....

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION